Skip to main navigation Skip to search Skip to main content

Assessment of the impact of social deprivation, distance to hospital and time to diagnosis on survival in idiopathic pulmonary fibrosis

  • Rashmi Shankar
  • , Charaka M Hadinnapola
  • , Allan B Clark
  • , Huzaifa Adamali
  • , Nazia Chaudhuri
  • , Lisa G Spencer
  • , Andrew M Wilson

Research output: Contribution to journalArticlepeer-review

111 Downloads (Pure)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive condition associated with a variable prognosis. The relationship between socioeconomic status or distance travelled to respiratory clinics and prognosis is unclear. To determine whether socioeconomic status, distance to hospital and time to referral affects survival in patients with IPF. In this retrospective cohort study, we used data collected from the British Thoracic Society Interstitial Lung Diseases Registry, between 2013 and 2021 (n = 2359) and calculated the quintile of Index of Multiple Deprivation 2019 score, time from initial symptoms to hospital attendance and distance as the linear distance between hospital and home post codes. Survival was assessed using Cox proportional hazards models. There was a significant association between increasing quintile of deprivation and duration of symptoms prior to hospital presentation, Gender Age Physiology (GAP) index and receipt of supplemental oxygen and antifibrotic therapies at presentation. The most deprived patients had worse overall survival compared to least deprived after adjusting for smoking status, GAP index, distance to hospital and time to referral (HR = 1.39 [1.11, 1.73]; p = 0.003). Patients living furthest from a respiratory clinic also had worse survival compared to those living closest (HR = 1.29 [1.01, 1.64]; p = 0.041). The most deprived patients with IPF have more severe disease at presentation and worse outcomes. Living far from hospital was also associated with poor outcomes. This suggests inequalities in access to healthcare and requires consideration in delivering effective and equitable care to patients with IPF. [Abstract copyright: Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.]
Original languageEnglish
Article number107612
Pages (from-to)1-7
Number of pages7
JournalRespiratory medicine
Volume227
Early online date25 Apr 2024
DOIs
Publication statusPublished online - 25 Apr 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors

Data Availability Statement

Data access for the British Thoracic Society Interstitial Lung Disease Registry is available at https://www.brit-thoracic.org.uk/quality-improvement/bts-clinical-data-policy-and-data-access/

Funding

AW RS ACreceived funding from the University of East Anglia to undertake the study. Grant reference MED10 MR3. www.uea.ac.uk. The design, data collection, analysis, and reporting were performed independently by the authors.AMW: Institutional research funding from Aseptika, Brainomix, Celgene Corporation, GlaxoSmithKline and Insmed. Speaker fees from Boehringer Ingelheim. Support to attend meeting from Chiesi.NC: Institutional research funding from Boehringer Ingelheim. Consultancy fees from Boehringer Ingelheim, Vicor and Bridge therepeutics. Speaker fees from Boehringer Ingelheim and Astra Zeneca. AW RS ACreceived funding from the University of East Anglia to undertake the study. Grant reference MED10\u202FMR3. www.uea.ac.uk . The design, data collection, analysis, and reporting were performed independently by the authors.

FundersFunder number
University of East AngliaMED10 MR3
University of East Anglia

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Idiopathic pulmonary fibrosis
    • Travelling distance
    • Socioeconomic status
    • Access to care
    • Social class
    • Survival

    Fingerprint

    Dive into the research topics of 'Assessment of the impact of social deprivation, distance to hospital and time to diagnosis on survival in idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

    Cite this